Tim A. Kanters

Update of the Dutch manual for costing studies in health care

Tim A. Kanters, Clazien Bouwmans, Naomi van der Linden et al. · PLoS ONE · 2017 · 276 citations · Full text

Public Affairs, Health Policy, Health Economics +16

Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow‐up

Deniz Güngör, Michelle E. Kruijshaar, Iris Plug et al. · Journal of Inherited Metabolic Disease · 2015 · 67 citations · Full text

Medicine, Internal Medicine, Functional Assessment +15

Burden of illness of Pompe disease in patients only receiving supportive care

Tim A. Kanters, M.L.C. Hagemans, Nadine A. M. E. van der Beek et al. · Journal of Inherited Metabolic Disease · 2011 · 38 citations · Full text

Pharmacy, Internal Medicine, Cost-effectiveness Analysis +16

Potential cost savings owing to the route of administration of oncology drugs

M Franken, Tim A. Kanters, Jules L.L.M. Coenen et al. · Anti-Cancer Drugs · 2018 · 36 citations · Full text

Pharmacy, Hospital Pharmacy, Pharmacoeconomics +15

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease

Tim A. Kanters, Iris Hoogenboom-Plug, Maureen Rutten‐van Mölken et al. · Orphanet Journal of Rare Diseases · 2014 · 34 citations · Full text

Pharmacy, Pediatrics, Pharmacoeconomics +17